These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35466928)

  • 21. Diagnostic value of triglyceride and cystatin C ratio in diabetic kidney disease: a retrospective and prospective cohort study based on renal biopsy.
    Wei J; Wang B; Shen FJ; Zhang TT; Duan Z; Zhou DM
    BMC Nephrol; 2022 Jul; 23(1):270. PubMed ID: 35896961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol.
    Gooding KM; Lienczewski C; Papale M; Koivuviita N; Maziarz M; Dutius Andersson AM; Sharma K; Pontrelli P; Garcia Hernandez A; Bailey J; Tobin K; Saunavaara V; Zetterqvist A; Shelley D; Teh I; Ball C; Puppala S; Ibberson M; Karihaloo A; Metsärinne K; Banks RE; Gilmour PS; Mansfield M; Gilchrist M; de Zeeuw D; Heerspink HJL; Nuutila P; Kretzler M; Welberry Smith M; Gesualdo L; Andress D; Grenier N; Shore AC; Gomez MF; Sourbron S;
    BMC Nephrol; 2020 Jun; 21(1):242. PubMed ID: 32600374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
    Huang HX; Shen LL; Huang HY; Zhao LH; Xu F; Zhang DM; Zhang XL; Chen T; Wang XQ; Xie Y; Su JB
    Diabetes Metab J; 2021 Nov; 45(6):868-879. PubMed ID: 33752319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes.
    Guo S; Wang M; Yu Y; Yang Y; Zeng F; Sun F; Li Q; He M; Li Y; Wen J; Gong W; Zhang Z
    BMC Endocr Disord; 2020 Jul; 20(1):103. PubMed ID: 32660469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of new biomarkers for the diagnosis of nephropathy associated with diabetes type 2.
    Żyłka A; Gala-Błądzińska A; Rybak K; Dumnicka P; Drożdż R; Kuśnierz-Cabala B
    Folia Med Cracov; 2015; 55(4):21-33. PubMed ID: 26867117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.
    Carlsson AC; Nowak C; Lind L; Östgren CJ; Nyström FH; Sundström J; Carrero JJ; Riserus U; Ingelsson E; Fall T; Ärnlöv J
    Ups J Med Sci; 2020 Feb; 125(1):37-43. PubMed ID: 31805809
    [No Abstract]   [Full Text] [Related]  

  • 27. Urinary orosomucoid 1 protein to creatinine ratio as a potential biomarker for early screening of kidney impairment in type-2 diabetes patients.
    Wang H; Bao X; Ma Y; Shan X; Huang C
    Nephrology (Carlton); 2020 Sep; 25(9):667-675. PubMed ID: 32147922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hip Fracture Risk According to Diabetic Kidney Disease Phenotype in a Korean Population.
    Lee SE; Yoo J; Kim KA; Han K; Choi HS
    Endocrinol Metab (Seoul); 2022 Feb; 37(1):148-158. PubMed ID: 35255607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum myeloid-related protein 8/14 is a potential predictor of diabetic kidney disease.
    Gu W; Cui J; Shi M; Zhang R; Tan D; Zhang X; Zhang H
    Discov Med; 2020; 30(160):97-105. PubMed ID: 33382965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of renal damage markers in the diagnosis of early stages of kidney injury in patients with latent autoimmune diabetes in adults.
    Tsaryk I; Pashkovska N
    J Med Life; 2022 Jun; 15(6):792-796. PubMed ID: 35928354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum hemoglobin concentration and risk of renal function decline in early stages of diabetic kidney disease: a nationwide, biopsy-based cohort study.
    Yamanouchi M; Furuichi K; Shimizu M; Toyama T; Yamamura Y; Oshima M; Kitajima S; Hara A; Iwata Y; Sakai N; Oba Y; Matsuoka S; Ikuma D; Mizuno H; Suwabe T; Hoshino J; Sawa N; Yuzawa Y; Kitamura H; Suzuki Y; Sato H; Uesugi N; Ueda Y; Nishi S; Yokoyama H; Nishino T; Samejima K; Kohagura K; Shibagaki Y; Makino H; Matsuo S; Ubara Y; Wada T
    Nephrol Dial Transplant; 2022 Feb; 37(3):489-497. PubMed ID: 34028524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitus.
    Khurana I; Howard NJ; Maxwell S; Du Preez A; Kaipananickal H; Breen J; Buckberry S; Okabe J; Al-Hasani K; Nakasatien S; Himathongkam T; Cooper ME; Maple-Brown L; Thewjitcharoen Y; Brown A; El-Osta A
    Diabetes Res Clin Pract; 2023 Oct; 204():110918. PubMed ID: 37748713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study.
    Sasso FC; Pafundi PC; Gelso A; Bono V; Costagliola C; Marfella R; Sardu C; Rinaldi L; Galiero R; Acierno C; Caturano A; de Sio C; De Nicola L; Salvatore T; Nevola R; Adinolfi LE; Minutolo R;
    Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):923-930. PubMed ID: 31377186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of increased circulating macrophage inhibitory protein-5 in patients with type 2 diabetes mellitus.
    Zhao B; Zhang M; Xie J; Jiang T; Li J; Yang Z
    Int Immunopharmacol; 2022 Aug; 109():108916. PubMed ID: 35679662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
    Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes.
    Zhu H; Liu X; Zhang C; Li Q; An X; Liu S; Wu L; Zhang B; Yuan Y; Xing C
    J Diabetes Complications; 2019 Nov; 33(11):107419. PubMed ID: 31473080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normoalbuminuric diabetic kidney disease.
    Chen C; Wang C; Hu C; Han Y; Zhao L; Zhu X; Xiao L; Sun L
    Front Med; 2017 Sep; 11(3):310-318. PubMed ID: 28721497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac Autonomic Dysfunction Is Associated With Risk of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
    Zeng H; Liu J; Chen Z; Yu P; Liu J
    Front Endocrinol (Lausanne); 2022; 13():900465. PubMed ID: 35846280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of Parkinson's disease according to diabetic kidney disease status in a Korean population.
    Lee SE; Yoo J; Choi HS; Han K; Kim KA
    Parkinsonism Relat Disord; 2022 Jul; 100():13-18. PubMed ID: 35667188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.